Showing results (31-40 of 53) with videos related to
Sort By:
Pageof 6
Rapid Communications in Mass Spectrometry : RCM|March 31, 2007
MSE with mass defect filtering for in vitro and in vivo metabolite identificationKevin P Bateman, Jose Castro-Perez, Mark Wrona, et al.Rapid Communications in Mass Spectrometry : RCM|October 15, 2008
Fractional mass filtering as a means to assess circulating metabolites in early human clinical studiesPhilip R Tiller, Sean Yu, Kevin P Bateman, et al.Journal of the American Society for Mass Spectrometry|September 2, 2020
Intact Protein Mass Spectrometry for Therapeutic Protein Quantitation, Pharmacokinetics, and Biotransformation in Preclinical and Clinical Studies: An Industry PerspectiveJohn F Kellie, John C Tran, Wenying Jian, et al.Journal of Pharmaceutical and Biomedical Analysis|April 25, 2018
Extractability-mediated stability bias and hematocrit impact: High extraction recovery is critical to feasibility of volumetric adsorptive microsampling (VAMS) in regulated bioanalysisIris Xie, Yang Xu, Melanie Anderson, et al.Analytical Chemistry|January 31, 2009
High-sensitivity nanoLC-MS/MS analysis of urinary desmosine and isodesmosineMichel Boutin, Carl Berthelette, François G Gervais, et al.Analytical Chemistry|May 15, 2007
High-throughput cytochrome P450 inhibition assays using laser diode thermal desorption-atmospheric pressure chemical ionization-tandem mass spectrometryJin Wu, Christopher S Hughes, Pierre Picard, et al.Journal of Pharmaceutical and Biomedical Analysis|June 21, 2020
Development of an automated and High throughput UHPLC/MS based workflow for cleaning verification of potent compounds in the pharmaceutical manufacturing environmentHuaming Sheng, Dae Kim, Alexander S Chin, et al.Bioorganic & Medicinal Chemistry Letters|January 12, 2010
The discovery of MK-0674, an orally bioavailable cathepsin K inhibitorElise Isabel, Kevin P Bateman, Nathalie Chauret, et al.Journal of Medicinal Chemistry|February 16, 2007
Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524)Claudio F Sturino, Gary O'Neill, Nicolas Lachance, et al.Bioorganic & Medicinal Chemistry Letters|November 11, 2006
In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolitesDeborah A Nicoll-Griffith, Carmai Seto, Yves Aubin, et al.Pageof 6